natgillin/translations-raw huggingface dataset:
Monitoring of renal function may be indicated when boosted darunavir is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents. 
Praćenje funkcije bubrega može biti indicirano kada se pojačan darunavir daje u kombinaciji s tenofovir dizoproksilom, posebno u bolesnika s podležećom sistemskom ili bubrežnom bolešću ili u bolesnika koji uzimaju nefrotoksične lijekove.
For patients with renal impairment the Summary of Product Characteristics for clarithromycin should be consulted for the recommended dose. 
Za bolesnike s oštećenjem bubrega za preporučenu dozu mora se pročitati sažetak opisa svojstava lijeka za klaritromicin.
The use of boosted darunavir and these anticoagulants is not recommended. 
Ne preporučuje se istodobna primjena pojačanog darunavira i ovih antikoagulansa.
No adjustment of methadone dosage is required when initiating coadministration with darunavir /ritonavir. 
Prilagodba doziranja metadona nije potrebna kada se započinje istodobna primjena s darunavirom/ritonavirom.
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when coadministered with boosted darunavir. 
Nužan je oprez, te ako je dostupno, preporučuje se praćenje terapijskih koncentracija za ove antiaritmike kada se primjenjuju istodobno s pojačanim darunavirom.
# in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). 
#u tablici ispod) provodilo se s nižom dozom darunavira od preporučene ili uz različit režim doziranja (vidjeti dio 4.2 Doziranje).
The exposure to total darunavir and ritonavir after intake of darunavir/ritonavir 600/100 mg twice daily and darunavir/ritonavir 800/100 mg once daily as part of an antiretroviral regimen was generally lower during pregnancy compared with postpartum. 
Ukupna izloženost darunaviru i ritonaviru nakon primjene darunavira/ritonavira 600/100 mg dvaput na dan i darunavira/ritonavira 800/100 mg jedanput na dan kao dio antiretrovirusnog liječenja bila je općenito niža tijekom trudnoće u usporedbi s postpartalnim razdobljem.
darunavir/ritonavir N=80 
Ishodi u 48. tjednu darunavir/ritonavir N=80
Phenobarbital and phenytoin are expected to decrease plasma concentrations of darunavir and its pharmacoenhancer. 
Za fenobarbital i fenitoin se očekuje da smanje koncentracije darunavira i njegovog farmakokinetičkog pojačivača u plazmi. (indukcijom CYP450 enzima)
Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir (e.g. rifampicin, St John's wort, lopinavir). 
Moglo bi se očekivati da lijekovi koji induciraju aktivnost CYP3A povećavaju klirens darunavira i ritonavira, što bi rezultiralo nižim koncentracijama darunavira i ritonavira u plazmi (npr. rifampicin, gospina trava, lopinavir).
Co-administration with herbal preparations containing St John's wort (Hypericum perforatum) (see section 4.5). 
Istodobna primjena s biljnim pripravcima koji sadrže gospinu travu (Hypericum perforatum) (vidjeti dio 4.5).
CORTICOSTEROIDS 
KORTIKOSTEROIDI
The evidence of efficacy of darunavir/ritonavir 800/100 mg once daily is based on the analyses of 192 week data from the randomised, controlled, open-label Phase III trial ARTEMIS in antiretroviral treatment-naïve HIV-1 infected patients comparing darunavir/ritonavir 800/100 mg once daily with lopinavir/ritonavir 800/200 mg per day (given as a twice-daily or as a once-daily regimen). 
Djelotvornost darunavira od 800 mg jedanput na dan primijenjenog istodobno sa 100 mg ritonavira jedanput na dan u bolesnika prethodno neliječenih ART-om Dokaz djelotvornosti darunavira/ritonavira 800/100 mg jedanput na dan temelji se na analizi podataka dobivenih nakon 192 tjedna randomiziranog, kontroliranog, otvorenog ispitivanja faze III pod nazivom ARTEMIS, provedenog u bolesnika inficiranih virusom HIV-1, prethodno neliječenih ART-om, u kojem se uspoređivao darunavir/ritonavir 800/100 mg jedanput na dan s lopinavirom/ritonavirom 800/200 mg na dan (primijenjen u režimu dvaput na dan ili jedanput na dan).
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when coadministered with darunavir with low dose ritonavir. 
Nužan je oprez, te ako je dostupno, preporučuje se praćenje terapijskih koncentracija za ove antiaritmike kada se primjenjuju istodobno s darunavirom s niskom dozom ritonavira.
Immune system disorders uncommon immune reconstitution inflammatory syndrome, (drug) hypersensitivity 
Poremećaji imunološkog sustava manje često upalni sindrom imunološke rekonstitucije, preosjetljivost (na lijek)
In the morning, take one 600 milligram Darunavir Krka tablet together with 100 milligram ritonavir. 
- Ujutro uzmite jednu tabletu lijeka Darunavir Krka od 600 miligrama zajedno sa 100 miligrama ritonavira.
Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are 
Preporučeno je kliničko praćenje terapijskih učinaka i nuspojava
Concomitant administration of darunavir with low dose ritonavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity. 
Istodobna primjena darunavira s niskom dozom ritonavira i kvetiapina je kontraindicirana jer može povisiti toksičnost povezanu s kvetiapinom.
Lopinavir/ritonavir 533/133.3 mg twice daily lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38% darunavir Cmin ↓ 51% darunavir Cmax ↓ 21% lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% based upon non dose normalised values 
Lopinavir/ritonavir 533/133,3 mg dvaput na dan lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38% darunavir Cmin ↓ 51% darunavir Cmax ↓ 21% lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% na temelju normaliziranih vrijednosti neovisnih o dozi
An increase of systemic exposure to darunavir was observed when darunavir co-administered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day). 
Povišena sistemska izloženost darunaviru primijećena je kad je darunavir istodobno primjenjen sa 100 mg ritonavira i rifabutinom (150 mg jedanput svaki drugi dan).
Hepatobiliary disorders common increased alanine aminotransferase uncommon hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase 
Poremećaji jetre i žuči često povišena alanin aminotransferaza manje često hepatitis, citolitički hepatitis, hepatička steatoza, hepatomegalija, povišene transaminaze, povišena aspartat aminotransferaza, povišen bilirubin u krvi, povišena alkalna fosfataza u krvi, povišena gama-glutamiltransferaza
Appropriate laboratory testing should be conducted prior to initiating therapy with darunavir/ritonavir and patients should be monitored during treatment. 
Prije početka terapije darunavirom/ritonavirom moraju se provesti odgovarajuća laboratorijska ispitivanja, te se bolesnike mora pratiti tijekom liječenja.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with boosted darunavir is required. 
preporučuje se smanjiti dozu kolhicina ili prekinuti liječenje kolhicinom u bolesnika s normalnom funkcijom bubrega ili jetre.
Concomitant use of darunavir with low dose ritonavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. 
Istodobno uzimanje darunavira s niskom dozom ritonavira i kortikosteroida koji se metaboliziraju putem CYP3A (npr. flutikazonpropionat ili ostali kortikosteridi koji se primjenjuju inhaliranjem ili kortikosteroidi za nazalnu primjenu) mogu povećati rizik za razvoj sistemskih učinaka koritkosteroida, ukljućujući Cushingov sindrom i adrenalnu supresiju.
800/100 mg once daily N=343 
800/100 mg jedanput na dan N=343
Ritonavir inhibits CYP3A, thereby increasing the plasma concentrations of darunavir considerably. 
Ritonavir inhibiraju CYP3A te na taj način značajno povećavaju koncentracije darunavira u plazmi.
HIV-1 RNA < 50 copies/ml All patients 
HIV-1 RNK < 50 kopija/ml Svi bolesnici
The Darunavir Krka 400 and 800 milligram tablets are used to treat adults and children (3 years of age and above, at least 40 kilograms body weight) who are infected by HIV and who have not used antiretroviral medicines before. 
Tablete lijeka Darunavir Krka od 400 miligrama i 800 miligrama koriste se za liječenje odraslih i djece (u dobi od 3 godine i starije, tjelesne težine najmanje 40 kilograma) koji su zaraženi HIV-om i - prethodno nisu uzimali antiretrovirusne lijekove. - upojedinih bolesnika koji su već prije koristili antiretrovirusne lijekove (to će ustanoviti Vaš liječnik).
For information on cobicistat pharmacokinetic properties, consult the cobicistat Summary of Product Characteristics. 
Za informacije o farmakokinetičkim svojstvima kobicistata, pogledajte sažetak opisa svojstava lijeka za kobicistat.
Concomitant use of boosted darunavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. 
Istodobno uzimanje pojačanog darunavira i kortikosteroida koji se metaboliziraju putem CYP3A (npr. flutikazonpropionat ili ostali kortikosteridi koji se primjenjuju inhaliranjem ili kortikosteroidi za nazalnu primjenu) mogu povećati rizik za razvoj sistemskih učinaka koritkosteroida, ukljućujući Cushingov sindrom i adrenalnu supresiju.
Applicable to darunavir boosted with either ritonavir or cobicistat: 
Primjenjivo na darunavir pojačan bilo ritonavirom bilo kobicistatom:
The evidence of efficacy of darunavir co-administered with ritonavir (600/100 mg twice daily) in ART-experienced patients is based on the 96 weeks analysis of the Phase III trial TITAN in ARTexperienced lopinavir naïve patients, on the 48 week analysis of the Phase III trial ODIN in ARTexperienced patients with no DRV-RAMs, and on the analyses of 96 weeks data from the Phase IIb trials POWER 1 and 2 in ART-experienced patients with high level of PI resistance. 
Djelotvornost darunavira od 600 mg dvaput na dan primijenjenog istodobno sa 100 mg ritonavira dvaput na dan u bolesnika prethodno liječenih ART-om Dokaz djelotvornosti darunavira primijenjenog istodobno s ritonavirom (600/100 mg dvaput na dan) u bolesnika prethodno liječenih ART-om temelje se na analizi podataka dobivenih nakon 96 tjedana liječenja u ispitivanju TITAN faze III u bolesnika prethodno liječenih ART-om, a neliječenih lopinavirom, na analizi podataka dobivenih nakon 48 tjedana liječenja u ispitivanju ODIN faze III u bolesnika prethodno liječenih ART-om bez DRV RAM, i analizama podataka dobivenih nakon 96 tjedana u ispitivanjima POWER 1 i 2, faze IIb u bolesnika prethodno liječenih ART-om koji imaju visoki stupanj rezistencije na PI.
Indinavir 800 mg twice daily indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11% 
Indinavir 800 mg dvaput na dan indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11%
C-darunavir could be retrieved in faeces and urine, respectively. 
C-darunavira može se naći u stolici, odnosno mokraći.
Darunavir KrKa 600 mg film coated tablets must not be chewed or crushed. 
Darunavir Krka 600 mg filmom obložene tablete ne smiju se žvakati ili lomiti.
600 mg once daily efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction) 
600 mg jedanput na dan efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz zbog inhibicije CYP3A) (↓ darunavir zbog indukcije CYP3A)
For patients with renal or hepatic impairment colchicine with boosted darunavir is contraindicated (see sections 4.3 and 4.4). 
Za bolesnike s oštećenjem bubrega ili jetre kolhicin s pojačanim darunavirom je kontraindiciran (vidjeti dijelove 4.3 i 4.4).
Plasma concentrations of these medicinal products may be increased when co-administered with boosted darunavir, resulting in reduced serum cortisol concentrations. 
Koncentracije ovih lijekova u plazmi mogu biti povišene, kada se primjenjuju istodobno s pojačanim darunavirom, dovodeći do sniženih koncentracija kortizola u serumu.
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. 
- Nakon što počnete uzimati lijekove za liječenje HIV infekcije dodatno uz oportunističke infekcije, također se mogu javiti autoimuni poremećaji (stanje u kojem imunosni sustav napada zdravo tjelesno tkivo).
darunavir/ritonavir N=12 
Ishodi u 48. tjednu darunavir/ritonavir N=12
800 mg film-coated tablets: 
800 mg filmom obložene tablete:
If parenteral midazolam is co-administered with darunavir co-administered with low dose ritonavir it may cause a large increase in the concentration of this benzodiazepine. 
Ako se parenteralni midazolam istodobno primjenjuje s darunavirom istodobno primjenjenim s niskom dozom ritonavira to može izazvati velik porast koncentracija ovog benzodiazepina.
Co-administration of domperidone with boosted darunavir is contraindicated. 
Istodobna primjena domperidona s pojačanim darunavirom je kontraindicirana.
No dose adjustment for darunavir /ritonavir is recommended. 
Ne preporučuje se prilagodba doze darunavira/ritonavira.
Carbamazepine, clonazepam(to prevent seizures or to treat certain types of nerve pain) Colchicine (to treat gout or familial Mediterranean fever) Bosentan (to treat high blood pressure in the pulmonary circulation) Buspirone, clorazepate, diazepam, estazolam, flurazepam, midazolam when used as injection, zoldipem (sedative agents) 
(za liječenje depresije i tjeskobe) - maravirok (za liječenje HIV infekcije) - metadon (za liječenje ovisnosti o opijatima) - karbamazepin, klonazepam (za sprječavanje epileptičkih napadaja ili za liječenje određenih vrsta neurološke boli) - kolhicin (za liječenje gihta ili obiteljske mediteranske vrućice) - bosentan (za liječenje povišenog krvnog tlaka u plućnom krvotoku) - buspiron, klorazepat, diazepam, estazolam, flurazepam, midazolam kada se koristi u obliku injekcije, zolpidem (sedativi)
If concomitant use of boosted darunavir with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended. 
darunavira indicirana sa sildenafilom, vardenafilom ili tadalafilom, tada su preporučene sljedeće doze: jednokratna doza sildenafila ne prelazi 25 mg u 48 sati, jednokratna doza vardenafila ne prelazi 2,5 mg u 72 sata ili jednokratna doza tadalafila ne prelazi 10 mg u 72 sata.
Hepatobiliary disorders common hepatic enzyme increased uncommon hepatitis*, cytolytic hepatitis* 
Poremećaji jetre i žuči često povišeni jetreni enzimi manje često hepatitis*, citolitički hepatitis*
Monitoring of renal function may be indicated when darunavir coadministered with low dose ritonavir is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents. 
Praćenje funkcije bubrega može biti indicirano kada se darunavir istodobno primijenjen s niskom dozom ritonavira daje u kombinaciji s tenofovirdizoproksiloom, posebno u bolesnika s podležećom sistemskom ili bubrežnom bolešću ili u bolesnika koji uzimaju nefrotoksične lijekove.
Skin and subcutaneous tissue disorders common rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus uncommon angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation rare 
Poremećaji kože i potkožnog tkiva često osip (uključujući makularni, makulopapularni, papularni, eritematozni i osip koji svrbi), pruritus manje često angioedem, generalizirani osip, alergijski dermatitis, urtikarija, ekcem, eritem, hiperhidroza, noćna znojenja, alopecija, akne, suha koža, pigmentacija noktiju rijetko
The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg twice daily. 
Ukupni učinak ritonavira kao farmakokinetičkog pojačivača očitovao se u približno 14 puta većoj sistemskoj izloženosti darunaviru kada se primijeni jednokratna peroralna doza od 600 mg darunavira u kombinaciji sa 100 mg ritonavira dvaput na dan.
The maraviroc dose should be 150 mg twice daily when co-administered with darunavir with low dose ritonavir. 
Doza maraviroka mora biti 150 mg dvaput na dan kada se primjenjuje istodobno s darunavirom s niskom dozom ritonavira bile su sukladne s podacima u anamnezi.
Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when coadministered with darunavir coadministered with low dose ritonavir. 
Za lovastatin i simvastatin se očekuje značajno povišenje koncentracija u plazmi kada se primjenjuju istodobno s darunavirom primijenjenim s niskom dozom ritonavira. (inhibicija CYP3A)
Combination of rifampicin with darunavir with concomitant low dose ritonavir (see section 4.5). 
Kombinacija rifampicina s darunavirom uz istodobno nisku dozu ritonavira (vidjeti dio 4.5).
600/100 mg twice daily N=296 
600/100 mg dvaput na dan N=296
ODIN is a Phase III, randomised, open-label trial comparing darunavir/ritonavir 800/100 mg once daily versus darunavir/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs (i.e. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV-1 RNA > 1,000 copies/ml. 
ODIN je randomizirano, otvoreno ispitivanje faze III u kojem se darunavir/ritonavir od 800/100 mg jedanput na dan naspram darunavira/ritonavira od 600/100 mg dvaput na dan u bolesnika prethodno liječenih ART-om inficirani virusom HIV-1, a na probiru pri uključivanju u ispitivanje testiranje genotipa u tih bolesnika nije pokazalo mutacije povezane s rezistencijom na darunavir (tj. V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V), dok je probir HIV-1 RNK u plazmi bio > 1000 kopija/ml.
Limited data is available in patients with HIV-1 clades other than B. 
Za bolesnike s podtipovima HIV-1, osim podtipa B, dostupni su ograničeni podaci.
Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). 
Ispitivanja su bila provedena s nižim dozama daruanvira od preporučanih ili s različitim režimom doziranja (vidjeti dio 4.2 Doziranje).
Therefore the same once daily dosage may be used in treatment-experienced adolescents aged 12 to < 18 years and weighing at least 40 kg without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10 
Stoga se isto doziranje od jedanput na dan može primijeniti u adolescenata koji su prethodno liječeni u dobi od 12 do < 18 godina s težinom najmanje 40 kg, koji nemaju mutacije povezane s rezistencijom na darunavir (DRV-RAM)* a imaju plazmatsku HIV-1 RNK < 100 000 kopija/ml i broj CD4+ stanica ≥ 100 stanica x 10
Silicified microcrystalline cellulose (Cellulose, microcrystalline; Silica, colloidal anhydrous) Magnesium stearate (E470b) 
celuloza, mikrokristalična krospovidon hidroksipropilceluloza silicijev dioksid, koloidni, bezvodni silicificirana mikrokristalična celuloza (celuloza, mikrokristalična; silicijev dioksid, koloidni, bezvodni) magnezijev stearat (E470b)
Co-administration of boosted darunavir and amiodarone, bepridil, dronedarone, ivabradine, quinidine, or ranolazine is contraindicated (see section 4.3). 
Istodobna primjena pojačanog darunavira i amiodarona, bepridila, dronedarona, ivabradina, kinidina ili ranolazina je kontraindicirana (vidjeti dio 4.3).
Bleeding in haemophiliac patients 
Krvarenje u bolesnika s hemofilijom
Caution should be exercised when combining one of these antineoplastic agents with boosted darunavir. 
Potreban je oprez kada se neki od tih antineoplastika kombinira s pojačanim darunavirom.
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e.g. indinavir, azole antifungals like clotrimazole). 
Istodobna primjena darunavira i ritonavira i drugih lijekova koji inhibiraju CYP3A može smanjiti klirens darunavira i ritonavira te može rezultirati povišenjem koncentracija darunavira i ritonavira u plazmi (npr. indinavir, antifungalni azoli poput klotrimazola).
In the evening, take one 600 milligram Darunavir Krka tablet together with 100 milligram ritonavir. 
- Navečer uzmite jednu tabletu lijeka Darunavir Krka od 600 miligrama zajedno sa 100 miligrama ritonavira.
The clinical trial data from ART-experienced patients (TITAN trial and the pooled analysis of the POWER 1, 2 and 3 and DUET 1 and 2 trials) showed that virologic response to darunavir coadministered with low dose ritonavir was decreased when 3 or more darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) were present at baseline or when these mutations developed during treatment. 
Podaci kliničkog ispitivanja provedenog među bolesnicima prethodno liječenih ARTom (ispitivanje TITAN i objedinjena analiza ispitivanja POWER 1, 2 i 3 te DUET 1 i 2) pokazali su da je virološki odgovor na darunavir primijenjen istodobno s niskom dozom ritonavira bio smanjen kada su na početku ispitivanja bile prisutne ili su se razvile tijekom liječenja 3 ili više mutacija, povezane s rezistencijom na darunavir (V11I, V32I, L33F, I47V, I50V, I54L ili M, T74P, L76V, I84V i L89V).
ANAESTHETIC Alfentanil 
Alfentanil
With Baseline CD4+ cell count (x 10 
S početnim brojem CD4+ stanica (x 10
≥ 30 kg-< 40 kg 675 mg darunavir /100 mg ritonavir once daily 
≥ 30 kg-< 40 kg 675 mg darunavir /100 mg ritonavir jedanput na dan
with darunavir/cobicistat 800/150 mg 
s darunavirom/kobicistatom 800/150 mg
Ritonavir may decrease plasma concentrations of voriconazole. 
Ritonavir može sniziti koncentracije vorikonazola u plazmi. (indukcija CYP450 enzima)
Pravastatin 40 mg single dose pravastatin AUC ↑ 81% pravastatin Cmin ND pravastatin Cmax ↑ 63% an up to five-fold increase was seen in a limited subset of subjects 
Pravastatin 40 mg jednokratna doza pravastatin AUC ↑ 81% pravastatin Cmin ND pravastatin Cmax ↑ 63% kod limitirane podskupine ispitanika primijećeno je povišenje do pet puta
A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with boosted darunavir has not been established. 
Nije ustanovljena sigurna i učinkovita doza sildenafila za liječenje pulmonalne arterijske hipertenzije s istodobnom primjenom pojačanog darunavira.
Gastrointestinal disorders very common diarrhoea, nausea common vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, pancreatic enzymes increased uncommon pancreatitis acute 
Poremećaji probavnog sustava vrlo često diarrhoea, nausea često povraćanje, bol u abdomenu, distenzija abdomena, dispepsija, flatulencija, povišeni enzimi pankreasa manje često akutni pankreatitis